Does the media prefer EBS or JNJ?

In the previous week, Johnson & Johnson had 68 more articles in the media than Emergent Biosolutions. MarketBeat recorded 79 mentions for Johnson & Johnson and 11 mentions for Emergent Biosolutions. Johnson & Johnson's average media sentiment score of 0.68 beat Emergent Biosolutions' score of 0.59 indicating that Johnson & Johnson is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Emergent Biosolutions 5 Very Positive mention(s) 0 Positive mention(s) 4 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Johnson & Johnson 38 Very Positive mention(s) 12 Positive mention(s) 15 Neutral mention(s) 6 Negative mention(s) 7 Very Negative mention(s) Positive

Which has preferable earnings and valuation, EBS or AAPG?

Emergent Biosolutions has higher revenue and earnings than Ascentage Pharma Group International. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Emergent Biosolutions $742.30M 0.49 $52.60M -$3.55 N/A Ascentage Pharma Group International $82.10M 16.64 -$177.71M N/A N/A

Does the media favor KARD or EBS?

In the previous week, Emergent Biosolutions had 8 more articles in the media than Kardigan. MarketBeat recorded 11 mentions for Emergent Biosolutions and 3 mentions for Kardigan. Emergent Biosolutions' average media sentiment score of 0.59 beat Kardigan's score of -0.47 indicating that Emergent Biosolutions is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Kardigan 0 Very Positive mention(s) 0 Positive mention(s) 0 Neutral mention(s) 1 Negative mention(s) 0 Very Negative mention(s) Neutral Emergent Biosolutions 5 Very Positive mention(s) 0 Positive mention(s) 4 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Does the media prefer EBS or ORIC?

In the previous week, Emergent Biosolutions had 3 more articles in the media than Oric Pharmaceuticals. MarketBeat recorded 11 mentions for Emergent Biosolutions and 8 mentions for Oric Pharmaceuticals. Emergent Biosolutions' average media sentiment score of 0.59 beat Oric Pharmaceuticals' score of 0.16 indicating that Emergent Biosolutions is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Emergent Biosolutions 5 Very Positive mention(s) 0 Positive mention(s) 4 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Oric Pharmaceuticals 1 Very Positive mention(s) 1 Positive mention(s) 2 Neutral mention(s) 2 Negative mention(s) 0 Very Negative mention(s) Neutral

Does the media favor TYRA or EBS?

In the previous week, Emergent Biosolutions had 7 more articles in the media than Tyra Biosciences. MarketBeat recorded 11 mentions for Emergent Biosolutions and 4 mentions for Tyra Biosciences. Emergent Biosolutions' average media sentiment score of 0.59 beat Tyra Biosciences' score of 0.13 indicating that Emergent Biosolutions is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Tyra Biosciences 0 Very Positive mention(s) 1 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Emergent Biosolutions 5 Very Positive mention(s) 0 Positive mention(s) 4 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Emergent Biosolutions (EBS) Competitors

$7.02 +0.22 (+3.16%)

Closing price 10/9/2026 03:59 PM Eastern

Extended Trading

$7.05 +0.02 (+0.30%)

As of 10/9/2026 07:59 PM Eastern

Compare

EBS vs. JNJ, AAPG, KARD, ORIC, and TYRA

Should you buy Emergent Biosolutions stock or one of its competitors? Emergent Biosolutions's main competitors and comparable companies include Johnson & Johnson (JNJ), Ascentage Pharma Group International (AAPG), Kardigan (KARD), Oric Pharmaceuticals (ORIC), and Tyra Biosciences (TYRA). Companies are selected based on similarities in market, industry, and size. These companies are all part of the "healthcare" sector.

How does Emergent Biosolutions compare to Johnson & Johnson?

Emergent Biosolutions (NYSE:EBS) and Johnson & Johnson (NYSE:JNJ) are both healthcare companies, but which is the superior stock? We will compare the two companies based on the strength of their profitability, risk, analyst recommendations, dividends, media sentiment, earnings, institutional ownership and valuation.

Johnson & Johnson has a net margin of 21.48% compared to Emergent Biosolutions' net margin of -22.95%. Johnson & Johnson's return on equity of 32.42% beat Emergent Biosolutions' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Emergent Biosolutions	-22.95%	16.35%	6.17%
Johnson & Johnson	21.48%	32.42%	13.35%

Emergent Biosolutions presently has a consensus price target of $10.00, indicating a potential upside of 42.35%. Johnson & Johnson has a consensus price target of $276.22, indicating a potential upside of 5.72%. Given Emergent Biosolutions' higher possible upside, research analysts clearly believe Emergent Biosolutions is more favorable than Johnson & Johnson.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Emergent Biosolutions	2 Sell rating(s)	1 Hold rating(s)	3 Buy rating(s)	0 Strong Buy rating(s)	2.17
Johnson & Johnson	0 Sell rating(s)	6 Hold rating(s)	18 Buy rating(s)	1 Strong Buy rating(s)	2.80

78.4% of Emergent Biosolutions shares are owned by institutional investors. Comparatively, 69.6% of Johnson & Johnson shares are owned by institutional investors. 6.0% of Emergent Biosolutions shares are owned by company insiders. Comparatively, 0.2% of Johnson & Johnson shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock is poised for long-term growth.

Johnson & Johnson has higher revenue and earnings than Emergent Biosolutions. Emergent Biosolutions is trading at a lower price-to-earnings ratio than Johnson & Johnson, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Emergent Biosolutions	$742.30M	0.49	$52.60M	-$3.55	N/A
Johnson & Johnson	$94.19B	6.68	$26.80B	$8.63	30.27

In the previous week, Johnson & Johnson had 68 more articles in the media than Emergent Biosolutions. MarketBeat recorded 79 mentions for Johnson & Johnson and 11 mentions for Emergent Biosolutions. Johnson & Johnson's average media sentiment score of 0.68 beat Emergent Biosolutions' score of 0.59 indicating that Johnson & Johnson is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Emergent Biosolutions	5 Very Positive mention(s)	0 Positive mention(s)	4 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Johnson & Johnson	38 Very Positive mention(s)	12 Positive mention(s)	15 Neutral mention(s)	6 Negative mention(s)	7 Very Negative mention(s)	Positive

Emergent Biosolutions has a beta of 2.28, suggesting that its share price is 128% more volatile than the broader market. Comparatively, Johnson & Johnson has a beta of 0.21, suggesting that its share price is 79% less volatile than the broader market.

Summary

Johnson & Johnson beats Emergent Biosolutions on 13 of the 17 factors compared between the two stocks.

How does Emergent Biosolutions compare to Ascentage Pharma Group International?

Emergent Biosolutions (NYSE:EBS) and Ascentage Pharma Group International (NASDAQ:AAPG) are both small-cap healthcare companies, but which is the superior business? We will compare the two businesses based on the strength of their valuation, profitability, earnings, dividends, institutional ownership, media sentiment, analyst recommendations and risk.

In the previous week, Emergent Biosolutions had 5 more articles in the media than Ascentage Pharma Group International. MarketBeat recorded 11 mentions for Emergent Biosolutions and 6 mentions for Ascentage Pharma Group International. Emergent Biosolutions' average media sentiment score of 0.59 beat Ascentage Pharma Group International's score of 0.11 indicating that Emergent Biosolutions is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Emergent Biosolutions	5 Very Positive mention(s)	0 Positive mention(s)	4 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Ascentage Pharma Group International	1 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	1 Negative mention(s)	0 Very Negative mention(s)	Neutral

Emergent Biosolutions has a beta of 2.28, meaning that its share price is 128% more volatile than the broader market. Comparatively, Ascentage Pharma Group International has a beta of 0.12, meaning that its share price is 88% less volatile than the broader market.

Emergent Biosolutions has higher revenue and earnings than Ascentage Pharma Group International.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Emergent Biosolutions	$742.30M	0.49	$52.60M	-$3.55	N/A
Ascentage Pharma Group International	$82.10M	16.64	-$177.71M	N/A	N/A

Emergent Biosolutions presently has a consensus price target of $10.00, suggesting a potential upside of 42.35%. Ascentage Pharma Group International has a consensus price target of $44.75, suggesting a potential upside of 205.88%. Given Ascentage Pharma Group International's stronger consensus rating and higher possible upside, analysts plainly believe Ascentage Pharma Group International is more favorable than Emergent Biosolutions.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Emergent Biosolutions	2 Sell rating(s)	1 Hold rating(s)	3 Buy rating(s)	0 Strong Buy rating(s)	2.17
Ascentage Pharma Group International	0 Sell rating(s)	0 Hold rating(s)	9 Buy rating(s)	2 Strong Buy rating(s)	3.18

Ascentage Pharma Group International has a net margin of 0.00% compared to Emergent Biosolutions' net margin of -22.95%. Emergent Biosolutions' return on equity of 16.35% beat Ascentage Pharma Group International's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Emergent Biosolutions	-22.95%	16.35%	6.17%
Ascentage Pharma Group International	N/A	N/A	N/A

78.4% of Emergent Biosolutions shares are owned by institutional investors. 6.0% of Emergent Biosolutions shares are owned by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company is poised for long-term growth.

Summary

Emergent Biosolutions beats Ascentage Pharma Group International on 9 of the 15 factors compared between the two stocks.

How does Emergent Biosolutions compare to Kardigan?

Kardigan (NASDAQ:KARD) and Emergent Biosolutions (NYSE:EBS) are both small-cap healthcare companies, but which is the better investment? We will compare the two businesses based on the strength of their earnings, risk, media sentiment, analyst recommendations, institutional ownership, dividends, valuation and profitability.

In the previous week, Emergent Biosolutions had 8 more articles in the media than Kardigan. MarketBeat recorded 11 mentions for Emergent Biosolutions and 3 mentions for Kardigan. Emergent Biosolutions' average media sentiment score of 0.59 beat Kardigan's score of -0.47 indicating that Emergent Biosolutions is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Kardigan	0 Very Positive mention(s)	0 Positive mention(s)	0 Neutral mention(s)	1 Negative mention(s)	0 Very Negative mention(s)	Neutral
Emergent Biosolutions	5 Very Positive mention(s)	0 Positive mention(s)	4 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Kardigan currently has a consensus price target of $42.25, suggesting a potential upside of 188.00%. Emergent Biosolutions has a consensus price target of $10.00, suggesting a potential upside of 42.35%. Given Kardigan's stronger consensus rating and higher possible upside, research analysts plainly believe Kardigan is more favorable than Emergent Biosolutions.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Kardigan	1 Sell rating(s)	1 Hold rating(s)	4 Buy rating(s)	0 Strong Buy rating(s)	2.50
Emergent Biosolutions	2 Sell rating(s)	1 Hold rating(s)	3 Buy rating(s)	0 Strong Buy rating(s)	2.17

Emergent Biosolutions has higher revenue and earnings than Kardigan. Kardigan is trading at a lower price-to-earnings ratio than Emergent Biosolutions, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Kardigan	N/A	N/A	-$191.94M	-$2.88	N/A
Emergent Biosolutions	$742.30M	0.49	$52.60M	-$3.55	N/A

78.4% of Emergent Biosolutions shares are held by institutional investors. 6.0% of Emergent Biosolutions shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company will outperform the market over the long term.

Kardigan has a net margin of 0.00% compared to Emergent Biosolutions' net margin of -22.95%. Emergent Biosolutions' return on equity of 16.35% beat Kardigan's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Kardigan	N/A	N/A	N/A
Emergent Biosolutions	-22.95%	16.35%	6.17%

Summary

Emergent Biosolutions beats Kardigan on 9 of the 14 factors compared between the two stocks.

How does Emergent Biosolutions compare to Oric Pharmaceuticals?

Emergent Biosolutions (NYSE:EBS) and Oric Pharmaceuticals (NASDAQ:ORIC) are both small-cap healthcare companies, but which is the better investment? We will compare the two businesses based on the strength of their media sentiment, valuation, profitability, risk, institutional ownership, analyst recommendations, earnings and dividends.

Emergent Biosolutions has a beta of 2.28, indicating that its stock price is 128% more volatile than the broader market. Comparatively, Oric Pharmaceuticals has a beta of 0.99, indicating that its stock price is 1% less volatile than the broader market.

Emergent Biosolutions has higher revenue and earnings than Oric Pharmaceuticals. Oric Pharmaceuticals is trading at a lower price-to-earnings ratio than Emergent Biosolutions, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Emergent Biosolutions	$742.30M	0.49	$52.60M	-$3.55	N/A
Oric Pharmaceuticals	N/A	N/A	-$129.47M	-$1.35	N/A

78.4% of Emergent Biosolutions shares are owned by institutional investors. Comparatively, 95.1% of Oric Pharmaceuticals shares are owned by institutional investors. 6.0% of Emergent Biosolutions shares are owned by insiders. Comparatively, 5.7% of Oric Pharmaceuticals shares are owned by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock will outperform the market over the long term.

Oric Pharmaceuticals has a net margin of 0.00% compared to Emergent Biosolutions' net margin of -22.95%. Emergent Biosolutions' return on equity of 16.35% beat Oric Pharmaceuticals' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Emergent Biosolutions	-22.95%	16.35%	6.17%
Oric Pharmaceuticals	N/A	-35.35%	-33.39%

In the previous week, Emergent Biosolutions had 3 more articles in the media than Oric Pharmaceuticals. MarketBeat recorded 11 mentions for Emergent Biosolutions and 8 mentions for Oric Pharmaceuticals. Emergent Biosolutions' average media sentiment score of 0.59 beat Oric Pharmaceuticals' score of 0.16 indicating that Emergent Biosolutions is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Emergent Biosolutions	5 Very Positive mention(s)	0 Positive mention(s)	4 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Oric Pharmaceuticals	1 Very Positive mention(s)	1 Positive mention(s)	2 Neutral mention(s)	2 Negative mention(s)	0 Very Negative mention(s)	Neutral

Emergent Biosolutions currently has a consensus price target of $10.00, suggesting a potential upside of 42.35%. Oric Pharmaceuticals has a consensus price target of $20.67, suggesting a potential upside of 72.37%. Given Oric Pharmaceuticals' stronger consensus rating and higher probable upside, analysts clearly believe Oric Pharmaceuticals is more favorable than Emergent Biosolutions.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Emergent Biosolutions	2 Sell rating(s)	1 Hold rating(s)	3 Buy rating(s)	0 Strong Buy rating(s)	2.17
Oric Pharmaceuticals	1 Sell rating(s)	1 Hold rating(s)	14 Buy rating(s)	0 Strong Buy rating(s)	2.81

Summary

Emergent Biosolutions beats Oric Pharmaceuticals on 9 of the 15 factors compared between the two stocks.

How does Emergent Biosolutions compare to Tyra Biosciences?

Tyra Biosciences (NASDAQ:TYRA) and Emergent Biosolutions (NYSE:EBS) are both small-cap healthcare companies, but which is the superior investment? We will compare the two businesses based on the strength of their analyst recommendations, earnings, profitability, risk, dividends, media sentiment, institutional ownership and valuation.

Tyra Biosciences presently has a consensus price target of $47.20, indicating a potential upside of 136.71%. Emergent Biosolutions has a consensus price target of $10.00, indicating a potential upside of 42.35%. Given Tyra Biosciences' stronger consensus rating and higher probable upside, equities research analysts plainly believe Tyra Biosciences is more favorable than Emergent Biosolutions.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Tyra Biosciences	1 Sell rating(s)	1 Hold rating(s)	11 Buy rating(s)	2 Strong Buy rating(s)	2.93
Emergent Biosolutions	2 Sell rating(s)	1 Hold rating(s)	3 Buy rating(s)	0 Strong Buy rating(s)	2.17

Tyra Biosciences has a net margin of 0.00% compared to Emergent Biosolutions' net margin of -22.95%. Emergent Biosolutions' return on equity of 16.35% beat Tyra Biosciences' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Tyra Biosciences	N/A	-46.39%	-43.07%
Emergent Biosolutions	-22.95%	16.35%	6.17%

In the previous week, Emergent Biosolutions had 7 more articles in the media than Tyra Biosciences. MarketBeat recorded 11 mentions for Emergent Biosolutions and 4 mentions for Tyra Biosciences. Emergent Biosolutions' average media sentiment score of 0.59 beat Tyra Biosciences' score of 0.13 indicating that Emergent Biosolutions is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Tyra Biosciences	0 Very Positive mention(s)	1 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
Emergent Biosolutions	5 Very Positive mention(s)	0 Positive mention(s)	4 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Tyra Biosciences has a beta of 0.75, meaning that its share price is 25% less volatile than the broader market. Comparatively, Emergent Biosolutions has a beta of 2.28, meaning that its share price is 128% more volatile than the broader market.

Emergent Biosolutions has higher revenue and earnings than Tyra Biosciences. Tyra Biosciences is trading at a lower price-to-earnings ratio than Emergent Biosolutions, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Tyra Biosciences	N/A	N/A	-$119.95M	-$2.40	N/A
Emergent Biosolutions	$742.30M	0.49	$52.60M	-$3.55	N/A

84.1% of Tyra Biosciences shares are owned by institutional investors. Comparatively, 78.4% of Emergent Biosolutions shares are owned by institutional investors. 12.5% of Tyra Biosciences shares are owned by insiders. Comparatively, 6.0% of Emergent Biosolutions shares are owned by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock will outperform the market over the long term.

Summary

Tyra Biosciences and Emergent Biosolutions tied by winning 8 of the 16 factors compared between the two stocks.

Get Emergent Biosolutions News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding EBS and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NYSE and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

EBS vs. The Competition

Export

Metric	Emergent Biosolutions	Biotechnology Industry	Healthcare Sector	NYSE Exchange
Market Cap	$349.17M	$3.84B	$7.16B	$22.94B
Dividend Yield	N/A	3.66%	2.53%	3.72%
P/E Ratio	-1.98	13.42	274.15	28.60
Price / Sales	0.49	1,234.38	635.98	15.12
Price / Cash	1.86	116.56	76.38	37.72
Price / Book	0.71	17.17	11.21	4.72
Net Income	$52.60M	-$22.69M	$3.50B	$1.07B
7 Day Performance	11.07%	-1.33%	-0.90%	0.35%
1 Month Performance	18.63%	-8.44%	-4.44%	-2.93%
1 Year Performance	-22.60%	14.02%	6.96%	9.26%

Emergent Biosolutions Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
EBS Emergent Biosolutions	4.2108 of 5 stars	$7.03 +3.2%	$10.00 +42.3%	-29.9%	$349.17M	$742.30M	N/A	900	Insider Trade
JNJ Johnson & Johnson	4.5154 of 5 stars	$272.16 +0.3%	$274.13 +0.7%	+36.8%	$653.61B	$94.19B	31.54	138,200	Trending News Upcoming Earnings Analyst Forecast
AAPG Ascentage Pharma Group International	3.8347 of 5 stars	$14.89 +0.2%	$46.43 +211.8%	-60.5%	$1.39B	$82.10M	N/A	767	News Coverage Analyst Forecast Short Interest Decrease
KARD Kardigan	3.1685 of 5 stars	$14.78 -0.1%	$42.25 +185.9%	N/A	$1.38B	N/A	N/A	241	Positive News Short Interest Increase
ORIC Oric Pharmaceuticals	3.1442 of 5 stars	$13.27 +0.8%	$20.18 +52.1%	-14.8%	$1.36B	N/A	N/A	111

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NYSE:EBS) was last updated on 10/10/2026 by MarketBeat.com Staff.

From Our Partners

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Emergent Biosolutions (EBS) Competitors

EBS vs. JNJ, AAPG, KARD, ORIC, and TYRA

How does Emergent Biosolutions compare to Johnson & Johnson?

Summary

How does Emergent Biosolutions compare to Ascentage Pharma Group International?

Summary

How does Emergent Biosolutions compare to Kardigan?

Summary

How does Emergent Biosolutions compare to Oric Pharmaceuticals?

Summary

How does Emergent Biosolutions compare to Tyra Biosciences?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

EBS vs. The Competition

Emergent Biosolutions Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Emergent Biosolutions (EBS) Competitors

EBS vs. JNJ, AAPG, KARD, ORIC, and TYRA

How does Emergent Biosolutions compare to Johnson & Johnson?

Is EBS or JNJ more profitable?

Do analysts rate EBS or JNJ?

Do institutionals & insiders have more ownership in EBS or JNJ?

Which has higher valuation & earnings, EBS or JNJ?

Does the media prefer EBS or JNJ?

Which has more volatility and risk, EBS or JNJ?

Summary

How does Emergent Biosolutions compare to Ascentage Pharma Group International?

Does the media prefer EBS or AAPG?

Which has more volatility and risk, EBS or AAPG?

Which has preferable earnings and valuation, EBS or AAPG?

Do analysts prefer EBS or AAPG?

Is EBS or AAPG more profitable?

Do insiders and institutionals hold more shares of EBS or AAPG?

Summary

How does Emergent Biosolutions compare to Kardigan?

Does the media favor KARD or EBS?

Do analysts prefer KARD or EBS?

Which has higher earnings and valuation, KARD or EBS?

Do insiders & institutionals hold more shares of KARD or EBS?

Is KARD or EBS more profitable?

Summary

How does Emergent Biosolutions compare to Oric Pharmaceuticals?

Which has more risk & volatility, EBS or ORIC?

Which has stronger earnings and valuation, EBS or ORIC?

Do institutionals and insiders hold more shares of EBS or ORIC?

Is EBS or ORIC more profitable?

Does the media prefer EBS or ORIC?

Do analysts rate EBS or ORIC?

Summary

How does Emergent Biosolutions compare to Tyra Biosciences?

Do analysts prefer TYRA or EBS?

Is TYRA or EBS more profitable?

Does the media favor TYRA or EBS?

Which has more risk & volatility, TYRA or EBS?

Which has preferable earnings & valuation, TYRA or EBS?

Do institutionals & insiders have more ownership in TYRA or EBS?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

EBS vs. The Competition

Emergent Biosolutions Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools